Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: harrowinc.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/11/2024 | $24.00 | Buy | Craig Hallum |
9/8/2022 | $17.00 | Buy | B. Riley Securities |
10/14/2021 | $16.00 | Buy | B. Riley Securities |
9/24/2021 | $15.00 | Buy | Aegis Capital |
7/2/2021 | $14.25 | Buy | Ladenburg Thalmann |
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York: H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel) September 9-11, 2024 Company will present at 8:00 a.m. ET on September 10, 2024 Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club) September 12, 2024 1x1 Meetings Only Cantor 2024 Global Healthcare Conference (InterContinental New York Barclay Hotel) September 17-19, 2024 Company will host a Fireside Chat at 2:30 p.m. ET on September 18, 2024 The Company will conduct one-on-one
Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for Vevizye®, intended for the treatment of moderate to severe dry eye disease in adult patients, which has not improved despite treatment with tear substitutes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729979383/en/Novaliq Receives Positive CHMP Opinion for Vevizye® in Dr
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings together top retina specialists, researchers, and industry leaders from around the globe to share the latest advancements and research in retinal health and treatment. "We are excited to attend the ASRS Annual Meeting and meet face-to-face with our growing customer base of U.S. retina specialists," said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. "We plan to discuss Harrow's expandin
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow's Mission to Make Its Products Accessible and Affordable Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program. IHEEZO, indicated for ocular anesthesia, is a low-viscosity topical ocular anesthetic gel with reliable efficacy, a proven safety profile, and simple administration. Other Harrow products available through the program include VIGAM
Successful Manufacture of TRIESENCE PPQ Batch Leads to Scheduling of Remaining Process Qualification Steps, Initial Inventory Build, and Pre-Commercial Activities Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Harrow also announced that the second
Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.'s proprietary fast‑dissolving Zydis® delivery technology to rapidly dissolve the tablet for absorption across the sublingual mucosa. The MELT-300 Phase 3 clinical trial is a randomized, double-blind, three-arm study comparin
Data Demonstrates Sustained Safety and Efficacy in Treating Signs and Symptoms of Dry Eye Disease Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, receiving VEVYE in each eye twice a day for 52 weeks. The one-year study results, published in Cornea, demonstrated VEVYE's sustained s
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 24th Annual Institutional Investor Conference (Beverly Hilton Hotel, Beverly Hills, CA) Format: Fireside Chat (In-Person), followed by 1x1 Investor Meetings Date/Time: Wednesday, May 22, 2024, through Thursday, May 23, 2024 Craig-Hallum 21st Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN) Format: 1x1 and Small Group Investor Meetings Date/Time: Wednesday, May 29, 2024 Investors interested in meeting with management during either conference should contact
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
DEFA14A - HARROW, INC. (0001360214) (Filer)
DEF 14A - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13D/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G/A - HARROW HEALTH, INC. (0001360214) (Subject)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $17.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $16.00
Aegis Capital initiated coverage of Harrow Health with a rating of Buy and set a new price target of $15.00
Ladenburg Thalmann initiated coverage of Harrow Health with a rating of Buy and set a new price target of $14.25
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW HEALTH, INC. (0001360214) (Issuer)
Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast
First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedures, retroactive to January 1, 2024. Recently signed IHEEZO supply agreements with seven multi-practice strategic accounts. U.S. Patent and Trademark Office recently granted new IHEEZO patent claims with an expiry through 2039. Sequential month-over-month growth in VEVYE total prescriptions, new prescriptions, prescribers, and refills. Covered lives fo
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update. Conference Call Details: Date: Tuesday, May 14, 2024 Time: 8:00 a.m. Ea
Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of $13.0 million. Cash from operating activities of $3.8 million. GAAP gross margin was 70% compared with 71% in the prior-year period. Core gross margin was 77% compared with 73% in the prior-year period. Cash and cash equivalents of $83 million, including investments in Eton Pharmaceuticals, as of December 31, 2023. Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, annou
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update. Conference Call Details: Date: Wednesday, March 20, 2
Third Quarter 2023 and Recent Selected Highlights: Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase of 2% over $33.5 million in the sequential quarter. GAAP net loss of $(4.4 million). Adjusted EBITDA of $9.2 million, an increase of 270% over $2.5 million in the prior‑year quarter. GAAP gross margin was flat at 71%, year-over-year. Core gross margin improved to 78% over the prior year's 72%. Cash and cash equivalents of $65.6 million as of September 30, 2023. Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. Harrow (NASDAQ:HROW), a leadi
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details: Date: Monday, November 13, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details: Date: Wednesday, August 9, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. ("Santen") under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen: U.S. Products: FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1%, a corticosteroid indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, corne
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Harrow Inc (NASDAQ:HROW) On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Har
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $26 to $30.
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday. Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings and sales results for its second quarter on Tuesday. KB Home reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.78. Quarterly sales came in at $1.71 billion, which beat the analyst consensus estimate of $1.651 billion, according to data from Benzinga Pro. KB Home shares gained 4.2% to $70.91 on Thursday. Here are some other big stocks recording gains in today’s session. Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares climbed 16% to $6.36
HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled TPST: 74% | Tempest Therapeutics shares are trading higher after the company announced the TPST-1120 arm improved all efficacy endpoints vs SoC control in a study. ACN: 9% | Accenture shares are trading higher. The company reported Q3 financial results
Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.'s proprietary fast‑dissolving Zydis® delivery technology to rapidly dissolve the tablet for absorption across the sublingual mucosa.The MELT-300 Phase 3 clinical trial is a randomized, double-blind, three-arm study comparing – at a 4:1:1 ratio – MELT-300, sublingua
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, receiving VEVYE in each eye twice a day for 52 weeks. The one-year study results, published in Cornea, demonstrated VEVYE's sustained safety and efficacy in treating the signs and symptoms of DED, underscoring its value in managing this